Good News At Last For GSK With Daprodustat, But Safety Scrutiny Awaits

Likely To Dominate US Market If Approved

 
• By Andrew McConaghie
  
Dialysis patient
While HIF inhibitors could replace ESAs in dialysis patients, use in non-dialysis patients offers the greatest potential • Source: Alamy

More from Business

More from Scrip